Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJ-040,714 in erosive gastro-esophageal reflux disease (Phase 2)
2005-004155-35Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CJ-040,714 in gastroesophageal reflux disease (GERD), sponsored by Pfizer. Primary endpoints: Fraction of time with esophageal pH < 4 and Duration of longest acid reflux event. Started Sep 2005; status: completed.
02
Drugs
CJ-040,714
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2005-004155-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004155-35.